Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets

This article was originally published in Start Up

Executive Summary

An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.

You may also be interested in...



Boehringer, Forma Strike Discovery Deal In Oncology

The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.

Pharma: Serious About Change?

Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.

Valuing Early-Stage Pharma Deals

The emphasis within the pharmaceutical industry right now is on capital efficiency. That's led a number of firms - and their venture backers - to make what a few years ago would have been a heretical decision: eschewing drug development in favor of cutting platform-related deals. And how have such deals been valued? An analysis by START-UP of average deal value from 2007 to 2010 for platform, preclinical and Phase I assets shows pharmaceutical licensers are approaching alliances with a "budget" mindset, with average deal values declining across all stages of drug development.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC091916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel